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Purpose: We evaluated the effects of combined PPARg agonist with bacillus
Calmette-Guérin in bladder cancer growth in vitro and in vivo, focusing on the
tissue remodeling mechanisms induced by bacillus Calmette-Guérin.
Materials and Methods: PPARs are a superfamily of nuclear receptors that are
transcription factors activated by ligands. Activation of PPARg, the  subtype,
causes proliferation inhibition or differentiation of tumor cells. Previously, we
reported that the inhibition of murine bladder tumor growth induced by bacillus
Calmette-Guérin, which is the standard treatment for patients with nonmuscle
invasive, high grade bladder cancer, increased PPARg expression in vitro and in
vivo. In vitro the cell growth inhibition induced by bacillus Calmette-Guérin was
enhanced by the PPARg agonist 15-d-PGJ2, raising the possibility that PPARg
activation may be a therapeutic modality for this disease.
Results: In MB49 cells bacillus Calmette-Guérin and 15-d-PGJ2 induced PPARg
expression, nuclear translocation and transcriptional activity. In vivo bacillus
Calmette-Guérin reduced tumor size, an effect that was partially reversed when
bacillus Calmette-Guérin was combined with the PPARg agonist rosiglitazone.
The same result was found when we analyzed the effect of the PPARg antagonist
BADGE (Fluka Chemical, Buchs, Switzerland) combined with bacillus Calmette-
Guérin. Analysis of the activation of macrophages and fibroblasts demonstrated
that rosiglitazone inhibited the tissue remodeling mechanisms induced by bacil-
lus Calmette-Guérin.
Conclusions: Results suggest that PPARg is involved in the antitumor action of
bacillus Calmette-Guérin. However, exogenous PPARg agonists would not be a
favorable therapeutic modality because they can inhibit the tissue remodeling
needed for an overall satisfactory bacillus Calmette-Guérin response.
Key Words: urinary bladder, urinary bladder neoplasms, PPAR gamma,
Abbreviations
and Acronyms
15-d-PGJ2 15-deoxy-12-14
prostaglandin J-2
-SMA -smooth muscle actin
BADGE bisphenol A diglycidyl
ether
BC bladder cancer
BCG bacillus Calmette-Guérin
MAC macrophage
MMP matrix metalloproteinase
NF-B nuclear factor-B
NMI nonmuscle invasive
PPAR peroxisome proliferator
activated receptor
PPRE PPARg responsive
element
RAW RAW264.7 cell
RO rosiglitazone
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2384 www.jurology.comBLADDER cancer is the second most
common tumor of the male urogenital
tract and an important worldwide
cause of death.1,2 The most common
histological type is transitional cell
carcinoma, representing more than
90% of cases.3 According to WHO in-
vasion status, BC is classified as NMI
and muscle invasive, the latter when
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cording to histological grade, BC can
be a papillary urothelial neoplasm of
low malignant potential, or low or
high grade carcinoma.4
BCG is the standard therapy to
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PPARg AND BACILLUS CALMETTE-GUÉRIN 2385vitro apoptosis of BC cells7 and inhibits in vivo mu-
rine tumor growth. It induces stromal remodeling,
including the differentiation of fibroblasts to myofi-
broblasts, collagen fiber deposits8 and MAC activa-
tion.9
PPARs are a superfamily of nuclear receptors
that are transcription factors activated by ligands.10
The most active natural agonist of PPARg is 15-d-
PGJ2.11 Antidiabetic thiazolidinedione compounds,
such as RO, are synthetic PPARg ligands.12 PPARg
activation causes the apoptosis, growth inhibition or
differentiation of BC cells.13,14 In addition, RO in-
duces cell cycle arrest in BC cell lines.15 PPARg is
expressed in normal urothelium and its expression
in BC is associated with lower recurrence.16,17
Previously, we noted that BCG induced PPARg
expression in murine BC cells in vitro and in vivo.18
In vitro 15-d-PGJ2 enhanced the MB49 BC cell line
death induced by BCG. Based on these results, the
combination of a PPARg agonist and BCG immuno-
therapy could be a potential tool for the treatment of
NMI BC.19 In the current study we evaluated this
hypothesis in vitro and in vivo using a MB49 BC
model with a special focus on the tissue remodeling
mechanisms induced by BCG.
MATERIALS AND METHODS
Cell Culture and BCG
The NIH-3T3 fibroblast cell line and MAC RAWs
(ATCC™) were maintained in Dulbecco’s modified Eagle’s
medium (31600-026, Gibco®). MB49 cells were cultured in
RPMI 1640 (31800-014, Gibco). All culture medium was
supplemented with 2 mM L-glutamine, 80 g/ml gentami-
cin and 5% to 10% fetal bovine serum in a humidified
atmosphere with 5% CO2. We used living organisms (3 
106 cfu/mg/ml) of an attenuated strain of Mycobacterium
tuberculosis (Pasteur 1172 P2).
Assays
Western blot. Subconfluent monolayers of MB49 cells
were treated with 2 mg/ml BCG with or without 10 M
15-d-PGJ2 (Cayman Chemical, Ann Arbor, Michigan) for
24 hours for total lysates and for 45 minutes for nuclear
extracts. NE-PER™ Nuclear and Cytoplasmic Extraction
Reagents were used to obtain the nuclear compartment.
Western blots were performed, as described previously.9
PPARg antibody (sc-H-100, Santa Cruz Biotechnology,
Santa Cruz, California) was used. To evaluate the loading
control, -actin (A5441, Sigma®) or histone H1 (FL-219,
Santa Cruz Biotechnology) antibody was used on stripped
membranes.
Gene reporter. To study PPARg transcriptional activity
MB49 and NIH-3T3 cells were transiently transfected with
20 g of a PPRE-luciferase reporter plasmid. MAC activa-
tion was evaluated by NF-B activation using transient
transfection with 20g of an NF-B-luciferase reporter plas-
mid in RAWs, as previously described.20 Luciferase activ-
ity was determined using the Dual-Luciferase® ReporterAssay System in a Triathler luminometer liquid scintilla-
tion counter (Hidex, Turku, Finland) and normalized to
constitutive Renilla activity.
Cell viability. Subconfluent monolayers of NIH-3T3 cells
growing in 24-well plates were treated with BCG (2 mg/ml),
15-d-PGJ2 (10 M), RO (10 M) or BADGE (10 M) for 48
hours. Cell viability was determined by cell counting with
trypan blue.
In Vivo Tumor Growth, Peritoneal
MAC Extraction and NO Production
Eight-week-old C57BL/6J male mice were subcutaneously
injected with 5  105 MB49 cells. Animals were treated
with intratumor BCG (2 mg/ml) with or without BADGE
(100 M/100 l per mouse) twice per week or RO
(8 mg/kg per day) in drinking water for 30 days. Control
mice were equally injected with saline solution. Tumor
size was measured twice per week and calculated using
the equation, (D  d)1/2, where D represents the larger
diameter and d represents the smaller diameter in mm. At
30 days MACs were obtained by washing the peritoneal
cavity with cool phosphate buffered saline-ethylenedi-
aminetetraacetic acid (0.02%). MACs were purified from
peritoneal washes by plastic adhesion for 2 hours.
NO was determined in 24-hour MAC culture superna-
tants from tumor bearing mice by the Griess reaction, as
previously described.8
Activity
Phagocytes. Phagocytic activity was determined as the
cfu and by Ziehl-Neelsen staining. To this end, 3  105
RAWs/ml were treated for 24 hours with RO (10 M) and
incubated for 1 hour with BCG (1 mg/ml). After washing
with phosphate buffered saline, cells were lysed with 5%
saponin and seeded on Löwenstein-Jensen solid medium.
Colonies were quantified after 30 days. Phagocytic activity
is reported in cfu/ml.
Ziehl-Neelsen staining was used to evaluate the num-
ber of bacilli in MACs and RAWs incubated with BCG for
2 hours, as seen as a pink area in cells. Treated cells were
fixed with methanol for 20 minutes, incubated in 100%
fuchsin for 1 hour and washed with bleach (3% HCl in 95%
ethyl alcohol) until discoloration. Glasses were incubated
with methylene blue for 20 minutes.
Matrix metalloproteinase. MMP-9 was determined as a
105 kDa collagenolytic band by zymography in culture
supernatants from peritoneal MACs deprived of serum for
24 hours, as previously described.21 It is expressed in
AU/104 cells.
Immunohistochemistry
-SMA expression was determined and Masson trichrome
staining was performed in paraffin embedded sections of
subcutaneous MB49 tumors from mice treated with BCG
with or without RO, as described previously.9
Ethics Statement
Mice from our Institute Animal Care Division were han-
dled in accordance with the international procedure for
Care and Use of Laboratory Animals. Protocols were ap-
proved by the Institutional Review Board CICUAL, Fac-
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tina.
Statistical Analysis
Three independent experiments were performed and only
one is shown. Results are expressed as the mean  SD of
6 replicates per group. Statistically significant values
were compared using ANOVA and the Bonferroni contrast
using the InStat® 3.01 with p 0.05 considered statisti-
cally significant.
RESULTS
BCG Induced PPARg and
Transcriptional Activity in MB49 Cell Line
BCG induced PPARg expression in the BC cell line
MB49 upon 24 hours of treatment (fig. 1, A). Under
basal conditions PPARg was absent in nuclear ex-
tracts, while it was translocated to the nucleus after
BCG or 15-d-PGJ2 alone or combined with BCG
treatment (fig. 1, B). A reporter gene assay with
PPRE showed that BCG and 15-d-PGJ2 increased
PPARg transcriptional activity, while combined
treatment of BCG plus 15-d-PGJ2 had a greater
effect than each of them separately (fig. 1, C). Thus,
the PPARg ligand increased the PPARg transcrip-
tional activity induced by BCG in MB49 cells.
In Vivo RO
Reversed tumor growth inhibition induced by
BCG. We evaluated the effect of BCG and RO on in
vivo MB49 tumor growth. Results revealed that RO
did not affect tumor development compared to con-
trol mice, while late in tumor progression it partially
reversed the inhibition caused by BCG administra-
tion (fig. 2, A). The same effect was recorded when
we analyzed the effect of the PPARg antagonist
BADGE (fig. 2, B). BADGE alone did not affect tu-
mor progression and it partially reversed the inhi-
Figure 1. A, PPARg expression with time in MB49 cells under B
expression. BCG increased PPARg expression fivefold over con
minutes after BCG, 15-d-PGJ2 or BCG plus 15-d-PGJ2 treatm
respectively, than in controls. C, PPARg transcriptional activity
plasmid and Renilla plasmid after 24 hours of different treatm
Renilla activity and referred to control. a, p 0.001 vs control. b, p 0bition caused by BCG treatment. The 2 experiments
indicated that use of a PPARg agonist or antagonist
partly affected the mechanisms of BCG antitumor
activity.
Inhibited BCG activated MACs. Tumor bearing
mice treated with BCG had an almost threefold
higher number of MACs than control mice. En-
hancement of the number of MACs by BCG was
associated with increased metabolic activity and NO
production. The number, metabolic activity and NO
production of MACs increased by BCG were par-
tially inhibited by BCG plus RO. Phagocytic activity
was not modified by BCG, while RO with or without
BCG inhibited this activity. MMP-9 activity of MACs
from BCG plus RO tumor bearing mice was decreased
compared to that in control mice (see table). Therefore,
in vivo activation of MACs was inhibited by RO.
MAC activation by BCG was also studied in
RAWs. As expected, BCG induced NF-B transcrip-
tional activity, which was completely inhibited upon
combined treatment with RO (fig. 3, A). As evalu-
ated by BCG according to cfu, RAW phagocytic ac-
tivity was significantly inhibited by RO (fig. 3, B). A
similar result was observed for the Ziehl-Neelsen
staining assay (fig. 3, C), on which fewer bacilli were
detected in RAWs treated with RO.
PPARg Ligands Inhibited
Fibroblast Activation Induced by BCG
We then analyzed fibroblast proliferation in the
presence of BCG with 15-d-PGJ2 or RO (fig. 4, A).
Fibroblast proliferation induced by BCG was signif-
icantly inhibited by 15-d-PGJ2 and RO. The effect of
the 2 PPARg agonists was reversed in the presence
of BADGE, indicating that the inhibition of fibro-
blast proliferation depended on ligand PPARg acti-
vation. To evaluate PPARg transcriptional activity
atment. -actin expression was used to assess PPARg relative
vel after 24-hour treatment. B, nuclear PPARg was detected 45
creased PPARg expression was 7.5, 5.5 and 3.5-fold greater,
49 subconfluent monolayers transfected with PPRE-luciferase
ctivity is shown as luciferase counts per second compared toCG tre
trol le
ent. In
in MB
ents. A
.0001 vs control. c, p 0.0001 vs BCG or 15-d-PGJ2.
ed. a,
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BCG increased PPARg transcriptional activity,
which was blocked by 15-d-PGJ2. This inhibition
was reversed in the presence of BADGE (fig. 4, B).
BCG Induced and RO Inhibited
Collagen and -SMA in MB49 Tumors
Intratumor inoculation of BCG induced an impor-
tant collagen deposit, seen as blue fibers using Masson
trichrome stain. This collagen deposit was lower in
tumors from mice treated with BCG plus RO (fig. 5,A).
Immunohistochemistry revealed that BCG induced
-SMA expression, while combined treatment with RO
decreased it (fig. 5, B). This suggests that the number
of activated fibroblasts was lower in tumors from mice
that received BCG plus RO therapy.
DISCUSSION
Intravesical BCG therapy is the best treatment to
date to prevent NMI BC progression and recur-
Figure 2. Subcutaneous MB49 tumor growth in mice. A, treatm
B, treatment with BCG, BADGE or BCG plus BADGE, as describ
Activation of MACs from tumor bearing mice was inhibited by
Mean  SD Control
MACs:
No. (106/mouse) 1.1  0.2
Metabolic activity (MTS 492 nm) 0.22  0.02
NO/nitrite (mol/106 cells) 5.00  0.04
Phagocytic index (BCG/MAC)‡ 12  3
MMP-9 activity (AU/106 cells) 5.00  2
* Bonferroni contrast and ANOVA p 0.05 vs BCG.
† Bonferroni contrast and ANOVA p 0.01 vs control.
‡ Assessed by counting number of bacilli in MACs after Ziehl-Neelsen staining.
§ Bonferroni contrast and ANOVA p 0.05 vs control.rence.5,15 The exact mechanism of action of BCG is
not fully known but it seems to evoke direct effects
on tumor cells and indirect effects mediated by the
immune system and stromal cells.5,6,9
PPARs are involved in the regulation of various
pathological processes and their activation causes
tumor growth inhibition or tumor cell differentia-
tion.13,14 We previously noted that BCG induced
PPARg expression in human and murine BC cells in
vitro as well as in MB49 tumors.18 In vitro growth
inhibition by BCG was enhanced by 15-d-PGJ2 and
reverted by BADGE. This suggested that BCG has
the ability to induce functional PPARg, which can
respond to the endogenous ligand. In the current
study BCG induced not only the expression but also
the translocation to the nucleus and transcriptional
activity of PPARg in BC MB49 cells. This activation
was also increased by 15-d-PGJ2. The nuclear trans-
location of NF-B and degradation of IkB- induced
by BCG were partially attenuated by 15-d-PGJ2
ith BCG, RO or BCG plus RO. a, p 0.01 vs control and BCG.
p 0.05 vs BCG. b, p 0.05 vs control.
 SD RO Mean  SD BCG Mean  SD BCG  RO*
 0.2 2.8  0.3† 1.5  0.2
 0.02 0.49  0.05† 0.30  0.03
 0.05 31.00  0.03† 17.60  0.1
 3§ 11  3 4  2
 2 7.75  2 3.35  1ent wRO
Mean
1.0
0.28
5.00
3
4.40
nside R
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inhibition of BC cells, in part by PPARg activation
and NF-B inactivation.
Paradoxically, in vivo we also noted that the syn-
thetic agonist RO reversed the inhibitory growth
activity induced by BCG. However, the inhibition of
tumor growth induced by BCG also depended on
PPARg activity since it was inhibited by BADGE.
Thus, PPARg was intrinsically involved in BCG an-
titumor activity. We speculate that the agonist RO
can affect other mechanisms involved in BCG im-
munotherapy, such as the host immune response
and tissue remodeling. PPARg agonists can abolish
immune activation.22–24 However, to our knowledge
there is no information on the role of PPARg activa-
tion in tissue remodeling in response to BCG. To
explain this effect, we focused on 2 key elements of
tumor stroma involved in the BCG mechanism of
action, including MACs and fibroblasts.
Figure 3. A, subconfluent RAW monolayers transfected with p
plasmid. Cells were treated or not treated with BCG (1 mg/ml
cps and referred to control. a, p 0.001 vs untreated. b, p 0
test p 0.0208. C, phagocytic activity. Arrow indicates BCG i
Figure 4. A, number of NIH-3T3 fibroblasts after 48 hours of d
vs 15-d-PGJ2 plus BCG. d, p 0.001 vs BCG. e, p 0.001 vs
monolayers transfected with PPRE-luciferase and Renilla plas
is expressed as luciferase cps vs Renilla activity and referre
15-d-PGJ2 plus BCG.Recent results showed that BCG not only targets
immune and BC cells but also induces the activation
of fibroblasts directly or indirectly through MAC
activation.9 Since MACs have a central role in the
regulation of the immune response as well as in
tissue remodeling, we evaluated some MAC param-
eters and their modulation by PPARg agonists. In
tumor bearing animals BCG treatment increased
the number, metabolic activity and NO production of
peritoneal MACs, while phagocytic capacity and
MMP-9 activity were not modified. Co-administra-
tion of BCG plus RO partially inhibited the number,
metabolic activity and NO production of MACs. RO
alone or combined with BCG decreased MAC phago-
cytic capacity, while BCG plus RO decreased the
activity of MMP-9 activity (which was used for its
migration) compared to controls. In vitro using MAC
RAWs we confirmed that RO inhibited NF-B acti-
vation and, thus, decreased phagocytic capacity.
containing element that responds to NF-B-luciferase and Renil
O (10 M) for 24 hours. Activity is shown as luciferase-to-Renil
BCG. B, RAW phagocytic capacity reported in cfu ml. a, Studen
AWs. Ziehl-Neelsen stain, reduced from  1,000.
t treatments. a, p 0.001 vs control. b, p 0.05 vs BCG. c, p 0.0
s BCG. B, PPARg transcriptional activity in NIH-3T3 subconflue
fter 24-hour treatment with BCG, 15-d-PGJ2 and BADGE. Activi
ontrol. a, p 0.01 vs control. b, p 0.01 vs BCG. c, p 0.01lasmid la
) and R la
.01 vs t tifferen 5
RO plu nt
mids a ty
d to c vs
ind
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inhibits the BCG antitumor response by inhibiting
MAC function.
Fibroblast activation was also involved in BCG
antitumor therapy. Previously, we observed that
BCG inhibits tumor growth by inducing the deposi-
tion of collagen fibers on surrounding tumor cells as
well as -SMA and fibroblast growth factor-2 expres-
sion.8,9 In this study the in vitro fibroblast prolifer-
ation induced by BCG was inhibited by PPARg ago-
nists. This was also evident in vivo, in which
decreased fibroblast activation and differentiation
were detected by a decrease in collagen deposition
and -SMA expression in tumors from mice treated
with BCG plus RO. Also, we detected that NIH-3T3
fibroblast treatment with BCG plus RO enhanced
collagenolytic MMP-2 activity (data not shown). The
inhibition of collagen and the increase in MMP-2 in
fibroblasts may explain the decreased collagen in
BCG plus RO treated MB49 tumors.
The antifibrotic activity of thiazolidinediones was
described in other experimental models, in which
thiazolidinediones inhibited collagen synthesis in
liver and lung fibrosis.25,26 Inhibition of the migra-
tion, proliferation and differentiation by RO was
noted in cultures of human lung fibroblasts and
pioglitazone inhibited matrix synthesis in dermal
fibroblasts.27,28 Taken together, our results and
those of others suggest that these PPARg agonists
are involved in the inhibition of some steps of tissue
remodeling. Particularly, RO treatment inhibits the
function not only of MACs but also of fibroblasts,
reversing part of the BCG response.
Since we tested only the effect of RO, we cannot
extrapolate our results to any other PPARg agonist.
However, this could be extended to other thiazoli-
dinediones because they have a similar mechanism
ure 5. Histological sections of subcutaneous MB49 tumors from
rows, light blue areas). Masson trichrome stain, scale bar repr
icates positive expression. Scale bar represents 100 m.of action for PPARg activation. Recently, a morepotent class of PPARg agonists was developed from a
series of 1,1-bis(3V-indolyl)-1-(p-substituted phenyl)
methanes. These compounds show significant anti-
tumor activity and they are significantly more po-
tent inhibitors of BC growth than RO.25,29 Since the
mechanism of action of this class of PPARg agonists
differs from that of thiazolidinediones, they could be
useful in combination with BCG. Thus, it is impor-
tant to perform further research in this area.
Notably, the subcutaneous implantation model
has some limitations compared with the clinical set-
ting. For example, BCG persistence at the injection
site in the extracellular compartment is distinctly
different than intravesical administration. In the
bladder normal urothelial cells as well as tumor cells
and MACs can engulf BCG. This is an important
step in the antitumor response. However, with
subcutaneous inoculation normal urothelial cells
are absent. Even with these limitations, this model
is a valid approach for studying tumor cells and
MACs.
CONCLUSIONS
Results show that BCG exerts its antitumor activity
in part by mediation by PPARg induction and acti-
vation in BC cells. It could be hypothesized that
endogenous PPARg agonist levels are involved in
this tumor cell death. However, exogenous PPARg
agonists such as RO would not be a favorable ther-
apeutic modality for BC because they can inhibit the
tissue remodeling needed for an overall satisfactory
BCG response.
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